Esketamine Nasal

艾司氯胺酮鼻喷雾剂

Report date: 2025/04/14 13:26:42

Base Information

Drug NameEsketamine Nasal
Drug Alias NameAFYX-004
ClassificationSmall molecules
Mechanisms of ActionGlutamate [NMDA] receptor antagonists
TargetsGlutamate [NMDA] receptor
Therapy Area/IndicationsCluster Headache
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAfyx Therapeutics A/S
China Registration ClassN/A

Develop Information

Active CompaniesAfyx Therapeutics A/S
Inactive CompaniesN/A
Active IndicationsCluster Headache
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A